Asia-Pacific Electronic Drug Delivery Systems Market, By Type (Electronic Infusion Pumps, Wearable Infusion Pumps, Electronic Injection Pens, Inhalers, Electronic Auto-Injectors, Electronic Inhalers, Electronic Capsules, Others), Component (Sensors, Wireless Communicator and Antennas, Micro Pumps and Flow Regulators, Drug Reservoir, Microcontroller, Others), Connectivity (Bluetooth Low Energy (BLE), Wi-Fi, Ethernet, NB-IoT, Others), System Type (Battery-Powered Systems, Rechargeable Systems), Application (Diabetes, Asthma and Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, Growth Hormone Therapy, Immunodeficiency Disease, Cardiovascular Disease, Thalassemia, Others), End User (Home Healthcare, Hospitals, Clinics, Ambulatory Centers, Others) – Industry Trends and Forecast to 2030.
Asia-Pacific Electronic Drug Delivery Systems Market Analysis and Size
According to a World Health Organization (WHO) fact sheet from 2017, CVDs are the leading cause of death, with 17.9 million deaths reported globally in 2016. Electronic drug delivery systems are portable devices that provide patients with convenient options such as simple drug administration, dose accuracy, quick administration, and improved patient adherence. With the introduction of technologically advanced minimally invasive electronic drug delivery systems, patients with chronic diseases can now self-administer their regular doses, reducing hospital visits and associated costs. Furthermore, various research studies are currently underway, which is expected to provide manufacturers with a competitive advantage in developing new and innovative electronic drug delivery systems, as well as other opportunities in the electronic drug delivery systems market.
Data Bridge Market Research analyses that the electronic drug delivery systems market which is USD 1,500.937 million in 2022, is expected to reach USD 3,384.88 million by 2030, at a CAGR of 10.7% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Asia-Pacific Electronic Drug Delivery Systems Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Electronic Infusion Pumps, Wearable Infusion Pumps, Electronic Injection Pens, Inhalers, Electronic Auto-Injectors, Electronic Inhalers, Electronic Capsules, Others), Component (Sensors, Wireless Communicator and Antennas, Micro Pumps and Flow Regulators, Drug Reservoir, Microcontroller, Others), Connectivity (Bluetooth Low Energy (BLE), Wi-Fi, Ethernet, NB-IoT, Others), System Type (Battery-Powered Systems, Rechargeable Systems), Application (Diabetes, Asthma and Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, Growth Hormone Therapy, Immunodeficiency Disease, Cardiovascular Disease, Thalassemia, Others), End User (Home Healthcare, Hospitals, Clinics, Ambulatory Centers, Others)
|
|
Countries Covered
|
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC)
|
|
Market Players Covered
|
GSK Plc. (U.K.), Galderma (Switzerland), Valeant Pharmaceuticals (Canada), Hisamitsu Pharmaceuticals Co. Inc. (Japan), Cipla Inc. (India), Glenmark (India), Johnson & Johnson Private Limited (U.S.), Novartis AG (Germany), Bayer AG (Germany), Crescita Therapeutics Inc. (Canada), Biofarmitalia S.R.L (Italy), Pharmatek Laboratories Inc. (U.S.), Skin Visible Pharmaceuticals, Inc. (U.S.), Mylan N.V. (U.S.), Pocono Coated Products LLC (U.S.),
|
|
Market Opportunities
|
|
Market Definition
Electronic drug delivery (e-drug delivery) systems are being developed to control drug dose delivery through easy dose monitoring, particularly in chronic and age-related diseases. E-drug delivery can be used in epilepsy, insulin drug delivery, cardiac ailments, and cancer therapy to monitor the correct dose of anaesthesia.
Asia-Pacific Electronic Drug Delivery Systems Market Dynamics
Drivers
- Rising number of cancer cases
A growing number of cancer, respiratory disease, and diabetic patients around the world may encourage the use of drug delivery devices and drive the overall market. According to data published by the International Agency for Research on Cancer 2020, one in every five people develops cancer during their lifetime, and one in every eight men and one in every eleven women die. Women are more likely than men to develop breast, colorectal, lung, cervical, and thyroid cancers. Lung and prostate cancer, are the most common among men, accounting for nearly one-third of all male cancers. The rising cancer burden drives up the adoption of drug delivery devices, which will contribute significantly to market growth during the forecast period.
Opportunities
- Innovation of new technologies
Drug delivery devices are being improved technologically to make them more patient-friendly, accessible, and accurate. In line with this, players are investing more in R&D and are constantly innovating new technologies and advanced drug delivery devices. Phillips-Medisize unveiled its Aria Smart Autoinjector platform in May 2021, enabling innovation, differentiation, and sustainability in the digital drug-delivery device market. This device includes advanced technologies such as a modular drug delivery platform that can accommodate a wide range of drug formulations and viscosities and built-in Bluetooth for connectivity to smartphones, tablets, and mobile apps.
Furthermore, Roche has developed a Port Delivery System with ranibizumab (PDS), a drug delivery implant that will free patients with wet age-related macular degeneration from the need for frequent eye injections in June 2021. As a result, all of the aforementioned factors are expected to boost market growth during the forecast period.
Restraints/Challenges
- Stringent regulatory process
The preference for alternative drug delivery modes limits the market growth during the forecast period. The most significant disadvantage of a controlled release drug delivery system is that it must be physically implanted and removed from the sites. Compounds with a high molecular weight are difficult to deliver.
This electronic drug delivery systems market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the electronic drug delivery systems market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In 2020, Bigfoot Biomedical received a USD 45 million grant to conduct late-stage clinical trials of its insulin management product, a connected insulin pen. In addition, the company has collaborated with Abbott Laboratories to gain access to Abbott's FreeStyle Libre glucose sensing technology.
Asia-Pacific Electronic Drug Delivery Systems Market Scope
The electronic drug delivery systems market is segmented on the basis of type, component, connectivity, system type, application, end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Electronic Infusion Pumps
- Wearable Infusion Pumps
- Electronic Injection Pens
- Inhalers
- Electronic Auto-Injectors
- Electronic Inhalers
- Electronic Capsules
- Others
Component
- Sensors
- Wireless Communicator
- Antennas
- Micro Pumps
- Flow Regulators
- Drug Reservoir
- Microcontroller
- Others
Connectivity
- Bluetooth Low Energy (BLE)
- Wi-Fi
- Ethernet
- NB-IoT
- Others
System Type
- Battery-Powered Systems
- Rechargeable Systems
Application
- Diabetes
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Multiple Sclerosis
- Growth Hormone Therapy
- Immunodeficiency Disease
- Cardiovascular Disease
- Thalassemia
- Others
End User
- Home Healthcare
- Hospitals
- Clinics
- Ambulatory Centers
- Others
Electronic Drug Delivery Systems Market Regional Analysis/Insights
The electronic drug delivery systems market is analyzed and market size insights and trends are provided by country, type, component, connectivity, system type, application, end user as referenced above.
The countries covered in the electronic drug delivery systems market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
Japan is expected to witness the highest CAGR during the forecast period due to the growing rate of heart disease with the development of the pharmaceutical sector. Furthermore, the high rate of asthma patients, particularly among the elderly, is driving market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The electronic drug delivery systems market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for electronic drug delivery systems market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the electronic drug delivery systems market. The data is available for historic period 2011-2021.
Competitive Landscape and Electronic Drug Delivery Systems Market Share Analysis
The electronic drug delivery systems market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to electronic drug delivery systems market.
Some of the major players operating in the electronic drug delivery systems market are:
- GSK Plc. (U.K.)
- Galderma (Switzerland)
- Valeant Pharmaceuticals (Canada)
- Hisamitsu Pharmaceuticals Co. Inc. (Japan)
- Cipla Inc. (India)
- Glenmark (India)
- Johnson & Johnson Private Limited (U.S.)
- Novartis AG (Germany)
- Bayer AG (Germany)
- Crescita Therapeutics Inc. (Canada)
- Biofarmitalia S.R.L (Italy)
- Pharmatek Laboratories Inc. (U.S.)
- Skin Visible Pharmaceuticals, Inc. (U.S.)
- Mylan N.V. (U.S.)
- Pocono Coated Products LLC (U.S.)
SKU-